Virtual Molecular Tumor Board on Metastatic Colorectal Cancer: Expert Advice on Managing Challenging Cases
Release date: 28-04-2021
Expiration date: 28-04-2022
The treatment landscape of metastatic colorectal cancer (mCRC) is changing rapidly. Advances in the molecular characterization of mCRC and increasing numbers of precision medicine treatments are adding to the complexity of treatment decision-making. Gain practical advice from experts in colorectal cancer on personalized treatment strategies for specific molecular subtypes of mCRC, as well as expert guidance on how to incorporate the latest advances into daily practice to optimize patient outcomes and quality of life. View presentations of challenging patient cases and roundtable discussions, with downloadable reference slides.
Jun Zhang, MD, PhD | Chair
Shanghai Jiaotong University School of Medicine
Jun Zhang, MD, PhD is Chief-Physician at the Department of Oncology, Rui Jin Hospital Institute of Digestive Surgery, Shanghai, China. He received his medical and doctoral degrees from Shanghai Jiao Tong University, Shanghai. During 2003 – 2006, Dr Zhang was a Visiting Professor at MD Anderson Cancer Center, Houston, Texas, US. His research interests are translational investigations related to chemotherapy and targeted therapy for gastric cancer and colorectal cancer, particularly focusing on biomarkers and metronomic chemotherapy. He has received three National Science Foundation grants, and his research has been published in international peer-reviewed journals, including Molecular Cancer, the International Journal of Cancer, and Cancer Letters. Currently, Dr Zhang serves as a faculty member in several international and domestic academic associations, including the Chinese Medical Association, China Anti-Cancer Association, Chinese Medical Doctor Association, and Chinese Society of Clinical Oncology.
Young Suk Park, MD, PhD
Samsung Medical Center
Sungkyunkwan University School of Medicine
Young Suk Park, MD, PhD is a Professor at the Division of Hematology-Oncology Department of Medicine, Samsung Medical Center – Sungkyunkwan University Medical School, Seoul, Korea. Dr Park received his medical degree from Seoul National University College of Medicine, Seoul, Korea. He has worked as the Director of the Clinical Trial Center in Samsung Medical Center and served as the Chairman of the Colorectal Cancer Subcommittee of the Korean Cancer Study Group (KCSG) and the Chairman of the Korean NET Forum. Dr Park has been involved in many national projects for the development of clinical trial support and training programs. His primary clinical interest is the treatment of gastrointestinal cancers, with an emphasis on conducting clinical trials as an active investigator; he has been the Primary Investigator of several clinical trials since 2002. In addition, Dr Park has written several book chapters and authored about 200 published articles in international journals.
Yanshuo Cao, MD, PhD
Peking University Cancer Hospital & Institute
Yanshuo Cao, MD is a Medical Oncologist at the Peking University Cancer Hospital & Institute, Beijing, China. Dr Cao received her medical degree from Peking University, Beijing, and completed her fellowship training in gastrointestinal medical oncology at the Beijing Cancer Hospital & Institute, Beijing, China. She spent 2 years as a Clinical Fellow at the Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Faculty of Medicine, University of Toronto, Toronto, Canada. She has been an author or co-author of more than 20 articles in peer-reviewed medical journals.
Jaw-Yuan Wang, MD, PhD
Kaohsiung Medical University Chung-Ho
Jaw-Yuan Wang, MD, PhD is a Professor of Surgery at Kaohsiung Medical University, Kaohsiung, Taiwan, where he also serves as Director of the Department of Medical Research of Kaohsiung Medical University Hospital. After receiving his medical and doctoral degrees from Kaohsiung Medical University, Professor Wang trained at the State University of New York in the US. He currently serves as the leader of the Colorectal Cancer Multidisciplinary Team, the Program Director of Robotic Surgery, and the Chairman of the Nutrition Support Council at Kaohsiung Medical University Hospital.
Professor Wang is an active member in numerous professional organizations and serves as President of the Society of Colon and Rectal Surgeons in Taiwan, Director of the Board of the Taiwan Society of Coloproctology, Executive Director of the Board of the Taiwan Society of Parenteral and Enteral Nutrition, and Executive Director of the Board of the Taiwan Genomic Medicine and Biomarker Society. He has been the recipient of numerous awards and published more than 300 peer-reviewed journal articles and 5 book chapters. Professor Wang also serves as an editor for several international journals, including the World Journal of Gastroenterology, Asian Journal of Surgery, Kaohsiung Journal of Medical Science and Oncology Letters. In 2020, he was invited to the Global Reach Committee of European Society of Coloproctology (ESCP).
Miaozhen Qiu, MD, PhD
Sun Yat-sen University Cancer Center
Miaozhen Qiu MD, PhD is an Associate Professor in the Department of Medical Oncology at the Sun-Yat-sen University Cancer Center, Guangzhou, China. She completed her post-doctoral research at Johns Hopkins Hospital, Baltimore, Maryland, US. Dr Qiu has received awards from the European Society for Medical Oncology and the United States Chinese Anti-Cancer Association Asia Fund for Cancer Research. She has also received five grants from the National Natural Science Foundation of China. Dr Qiu is a member of the American Society of Clinical Oncology and the European Society for Medical Oncology.
Yu Sunakawa, MD, PhD
St Marianna University School of Medicine
Yu Sunakawa, MD, PhD is a Medical Oncologist at St. Marianna University School of Medicine in Japan. He completed his postdoctoral research fellowship training at the University of Southern California/Norris Comprehensive Cancer Center, California, US. In 2011, Dr Sunakawa received board certification from the Japanese Society of Medical Oncology. Dr Sunakawa’s research interests are the identification and determination of molecular markers in cancerous tissues or blood that could predict cancer risk and clinical outcome in gastrointestinal cancer. He is also focusing on research regarding tumor immunity, and in 2014 he received a Merit Award from the American Society of Clinical Oncology for research on genetic variations in immune checkpoint-related genes. He has authored numerous publications on translational studies in gastrointestinal cancers.
Hideaki Bando, MD, PhD
Aichi Cancer Center Hospital
Nagoya, Aichi, Japan
Hideaki Bando, MD, PhD is Staff Physician in the Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan. Dr Bando received his medical degree from Asahikawa Medical College, Asahikawa, and was a visiting fellow of the Cancer Therapy Evaluation Program, Division of Cancer Treatment & Diagnosis, National Cancer Institute, National Institutes of Health in Bethesda, Maryland, US, before receiving his doctoral degree from Juntendo University, Tokyo. Dr Bando is a member of numerous professional organizations, including the American Society for Clinical Oncology, European Society for Medical Oncology, Japanese Society of Medical Oncology (JSMO), Japanese Cancer Association (JCA), Japanese Society of Gastroenterology, and the Japanese Society of Internal Medicine. He has received three Young Researchers Awards from JSMO, and in 2017 he was the recipient of the Incitement Award of the JCA. Dr Bando is the author or co-author of more than 30 peer-reviewed publications.
Xicheng Wang, MD, PhD
Department of Gastrointestinal Oncology
Peking University Cancer Hospital & Institute
Dr Xicheng Wang is an Associate Professor of Medical Oncology at Peking University Cancer Hospital in Peking, and specializes in gastrointestinal cancers. Dr Wang received his medical degree from Peking University Health Science Center in 2001, and subsequently studied at the Johns Hopkins University, Baltimore, US, where he was awarded a PhD in Physiology in 2006. He completed his residency and fellowship training at Peking University Cancer Hospital in 2012. His main research interests include precision medicine in colorectal cancer and hereditary gastrointestinal cancers.
Feng-Che Kuan, MD
Chang-Gung Memorial Hospital
Feng-Che Kuan, MD is a Medical Oncologist and is currently Visiting Staff at the Department of Hematology and Oncology, Chang Gung Memorial Hospital, Chia-Yi, Taiwan. He received his medical degree from Chang-Gung University School of Medicine, Taoyuan, Taiwan, and completed his residency at the Department of Internal Medicine and a fellowship at the Department of Hematology and Oncology, Chang Gung Memorial Hospital. In 2015, he acted as a Medical Consultant on the Colorectal Cancer Committee, National Health Research Institutes, Taiwan. Dr Kuan’s research interests include gastrointestinal malignancies, lung cancer, breast cancer, cancer of unknown primary origin, and cancer therapeutics. He is author and co-author of several publications in peer-reviewed journals, including British Journal of Cancer and Annals of Surgical Oncology. Dr Kuan is a member of the Taiwan Society of Internal Medicine, Chinese Society of Clinical Oncology, and American Society of Clinical Oncology.
- Transforming outcomes in mCRC: Increasing the role of personalized treatment strategies | Young Suk Park, MD, PhD
- Case #1: RAS & BRAF wild-type mCRC | Yanshuo Cao, MD, PhD
- Roundtable discussion: Continuum of care in mCRC without molecular alterations | Jaw-Yuan Wang, MD, PhD
- Case #2: BRAF-mutated mCRC | Miaozhen Qiu, MD, PhD
- Roundtable discussion: Treatment sequencing in BRAF-mutated mCRC | Yu Sunakawa, MD, PhD
- Case #3: MSI-H mCRC | Hideaki Bando, MD, PhD
- Roundtable discussion: When and how to use immunotherapy in MSI-H mCRC | Xicheng Wang, MD, PhD
- Case #4: HER2-amplified mCRC | Feng-Che Kuan, MD
- Roundtable discussion: When to consider HER2-targeted therapy, and what regimen to use | Jun Zhang, MD, PhD
The proposed educational activity is specifically designed for medical oncologists, gastroenterologists, surgical oncologists, and other healthcare professionals involved in the management of mCRC.
Upon completion of this educational activity, participants should be able to:
- Evaluate biomarker assessment to provide optimal personalized therapy in mCRC
- Determine best treatment strategies for mCRC without molecular alterations
- Select most appropriate sequential therapies for patients with BRAF-mutant mCRC and MSI-H mCRC
- Explain when and how to assess HER2 status in mCRC, and treatment approaches
Provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Jun Zhang has served as a speaker or a member of a speakers bureau for Roche, Sanofi, Pfizer, Merck, Heng Rui, BMS, MSD, and Taiho. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Young Suk Park has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Yanshuo Cao has no financial relationships to disclose. Any labeled/unapproved uses of drugs or products referenced in her presentation will be specified.
Jaw-Yuan Wang has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Miaozhen Qiu has no financial relationships to disclose. Any labeled/unapproved uses of drugs or products referenced in her presentation will be specified.
Yu Sanakawa has served as an advisor or consultant for Takeda and Bristol-Myers Squibb. He has served as a speaker or a member of a speakers bureau for Takeda, Merck Biopharma, Eli Lilly Japan, Taiho Pharma, Chugai Pharma, Yakult Honsha, Sanofi, Ono Pharma, Bristol-Myers Squibb, Bayer, and Daiichi Sankyo. Any unlabeled/unapproved uses of drug or products referenced in his presentation will be specified.
Hideaki Bando has served as an advisor or consultant for Bristol-Myers Squibb Japan and Merck Biopharma Japan. He has served as a speaker or a member of a speakers bureau for Taiho Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb Japan, Eli Lilly Japan, Merck Biopharma Japan, and Takeda Pharmaceutical. Any unlabeled/unapproved uses of drug or products referenced in his presentation will be specified.
Xicheng Wang has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Feng-Che Kuan has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.